Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from MEI Pharma ( (MEIP) ) is now available.
On August 5, 2025, Steven D. Wood resigned from the board of directors of MEI Pharma, Inc., with no disagreements regarding the company’s operations or policies. On the same day, Joshua Riezman, Managing Director at GSR Strategies, LLC, was elected to the board, reflecting a strategic alignment with GSR, a crypto market making and trading firm, which has an Asset Management Agreement with MEI Pharma.
Spark’s Take on MEIP Stock
According to Spark, TipRanks’ AI Analyst, MEIP is a Neutral.
MEI Pharma’s overall stock score is low, primarily due to significant financial performance challenges and poor valuation metrics. Weak revenue and profitability, declining asset base, and negative cash flow contribute to a fragile financial position. Additionally, technical indicators suggest a bearish trend, further impacting investor sentiment. Without clear guidance or positive corporate events, the stock’s outlook remains unfavorable.
To see Spark’s full report on MEIP stock, click here.
More about MEI Pharma
Average Trading Volume: 1,005,470
Technical Sentiment Signal: Buy
Current Market Cap: $33.65M
See more data about MEIP stock on TipRanks’ Stock Analysis page.